Find, compare & contact
Sabatolimab
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Sabatolimab API 2252262-24-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Sabatolimab. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Sabatolimab
- Synonyms:
- Anti-tim-3 monoclonal antibody mbg453 , Anti-tim3 checkpoint inhibitor mbg453 , Immunoglobulin g4 (226-proline,de-c-terminal-lysine), anti-(human hepatitis virus a cellular receptor 2) (human-mus musculus monoclonal clone nvs260714 .gamma.4-chain), disulfide with human-mus musculus monoclonal clone nvs260714 .kappa.-chain, dimer , Immunoglobulin g4-kappa, anti-(homo sapiens havcr2 (hepatitis a virus cellular receptor 2, t-cell immunoglobulin mucin family member 3, tim-3, tim3, timd3, cd366)), humanized monoclonal antibody , Sabatolimab
- Cas Number:
- 2252262-24-9
- DrugBank number:
- DB16322
- Unique Ingredient Identifier:
- 3L7R886Y06
General Description:
Sabatolimab, identified by CAS number 2252262-24-9, is a notable compound with significant therapeutic applications. Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).
Sabatolimab is a type of Intermediates
Pharmaceutical intermediates are a crucial category within the API (Active Pharmaceutical Ingredient) industry. These chemical compounds play a vital role in the synthesis of APIs, serving as building blocks or precursor molecules in the manufacturing process. Pharmaceutical intermediates are designed to undergo specific chemical transformations, enabling the production of targeted APIs with desired properties.
These intermediates are typically produced through complex organic synthesis, involving various chemical reactions and purification steps. They are carefully developed and optimized to ensure high purity, stability, and safety, meeting stringent regulatory requirements for pharmaceutical use.
Pharmaceutical intermediates offer several advantages in API production. Firstly, they enable the efficient and cost-effective synthesis of APIs by providing a well-defined starting material. This reduces the need for expensive or hard-to-obtain raw materials, streamlining the overall manufacturing process. Secondly, intermediates allow for fine-tuning of the chemical reactions, optimizing the yield and quality of the final API. This control over the synthesis process enhances the consistency and reproducibility of pharmaceutical manufacturing.
Moreover, pharmaceutical intermediates facilitate the development of new APIs and drug formulations. By modifying the structure or functional groups of the intermediate molecules, researchers can explore different chemical pathways and create novel compounds with improved therapeutic efficacy, reduced side effects, or enhanced bioavailability.
In summary, pharmaceutical intermediates are essential components in API synthesis, enabling efficient and controlled production of pharmaceutical compounds. Their versatility and role in driving innovation make them indispensable in the pharmaceutical industry.
